[go: up one dir, main page]

BRPI0411360A - anthranilamidapyridones vegfr-2 and vegfr-3 inhibitors - Google Patents

anthranilamidapyridones vegfr-2 and vegfr-3 inhibitors

Info

Publication number
BRPI0411360A
BRPI0411360A BRPI0411360-8A BRPI0411360A BRPI0411360A BR PI0411360 A BRPI0411360 A BR PI0411360A BR PI0411360 A BRPI0411360 A BR PI0411360A BR PI0411360 A BRPI0411360 A BR PI0411360A
Authority
BR
Brazil
Prior art keywords
vegfr
anthranilamidapyridones
inhibitors
antranylamydirpyrides
publicized
Prior art date
Application number
BRPI0411360-8A
Other languages
Portuguese (pt)
Inventor
Andreas Huth
Martin Krueger
Ludwig Zorn
Stuart Ince
Rolf Bohlmann
Karl-Heinz Thierauch
Andreas Menrad
Martin Haberey
Holger Hess-Stumpp
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0411360A publication Critical patent/BRPI0411360A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

"ANTRANILAMIDAPIRIDONAS INIBIDORAS DE VEGFR-2 E VEGFR-3". A presente invenção refere-se a novas antranilamidapiridonas inibidoras de VEGFR-2 e VEGFR-3 selecionadas que são piblicadas e sua aplicação como medicamento para o tratamento de doenças, que são causadas pela angiogênese persistente."VEGFR-2 AND VEGFR-3 INHIBITOR ANTRANYLAMYDIRPYRIDES". The present invention relates to novel selected VEGFR-2 and VEGFR-3 inhibiting anthranilamidapyridones which are publicized and their application as a medicament for the treatment of diseases which are caused by persistent angiogenesis.

BRPI0411360-8A 2003-06-13 2004-06-09 anthranilamidapyridones vegfr-2 and vegfr-3 inhibitors BRPI0411360A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10327719A DE10327719A1 (en) 2003-06-13 2003-06-13 VEGFR-2 and VEGFR-3 Inhibitory anthranylamide pyridones
PCT/EP2004/006236 WO2004111005A1 (en) 2003-06-13 2004-06-09 Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3

Publications (1)

Publication Number Publication Date
BRPI0411360A true BRPI0411360A (en) 2006-07-25

Family

ID=33520741

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411360-8A BRPI0411360A (en) 2003-06-13 2004-06-09 anthranilamidapyridones vegfr-2 and vegfr-3 inhibitors

Country Status (18)

Country Link
EP (1) EP1633713A1 (en)
JP (1) JP2006527228A (en)
KR (1) KR20060021887A (en)
CN (1) CN1805936A (en)
AU (1) AU2004247377A1 (en)
BR (1) BRPI0411360A (en)
CA (1) CA2526041A1 (en)
CR (1) CR8127A (en)
DE (1) DE10327719A1 (en)
EA (1) EA200501885A1 (en)
EC (1) ECSP066280A (en)
IL (1) IL171898A0 (en)
MX (1) MXPA05013586A (en)
NO (1) NO20060196L (en)
RS (1) RS20050831A (en)
UA (1) UA81323C2 (en)
WO (1) WO2004111005A1 (en)
ZA (1) ZA200600291B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060071812A (en) * 2004-12-22 2006-06-27 주식회사 엘지생명과학 Novel 3- (2-amino-6-pyridinyl) -4-hydroxyphenyl amine derivatives
WO2013103317A1 (en) * 2012-01-05 2013-07-11 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CN106496107A (en) * 2016-08-31 2017-03-15 浙江永宁药业股份有限公司 VEGFR inhibitor 2 and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71587C2 (en) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE10023486C1 (en) * 2000-05-09 2002-03-14 Schering Ag Ortho substituted anthranilic acid amides and their use as medicines
DE50213703D1 (en) * 2001-05-08 2009-09-03 Bayer Schering Pharma Ag SELECTIVE ANTHRANYLAMID PYRIDINAMIDES AS VEGFR-2 AND VEGFR-3 INHIBITORS
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
DE10228090A1 (en) * 2002-06-19 2004-01-15 Schering Ag New N-2-(pyridon-2-yl-methyl)-anthranilamide derivatives, are tyrosine kinase KDR and FLT inhibitors and angiogenesis inhibitors, useful e.g. for treating tumors, psoriasis or restenosis

Also Published As

Publication number Publication date
UA81323C2 (en) 2007-12-25
DE10327719A1 (en) 2005-01-20
CR8127A (en) 2006-05-29
KR20060021887A (en) 2006-03-08
IL171898A0 (en) 2006-04-10
WO2004111005A1 (en) 2004-12-23
AU2004247377A1 (en) 2004-12-23
RS20050831A (en) 2008-04-04
MXPA05013586A (en) 2006-03-09
JP2006527228A (en) 2006-11-30
CA2526041A1 (en) 2004-12-23
ECSP066280A (en) 2006-07-28
CN1805936A (en) 2006-07-19
EA200501885A1 (en) 2006-06-30
NO20060196L (en) 2006-01-12
ZA200600291B (en) 2007-03-28
EP1633713A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
BRPI0514841A (en) hedgehog signaling pyridyl inhibitors, their preparation process and composition comprising said inhibitors
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
CY1112932T1 (en) Suspensions SMAD7 FOR CNS DISEASE TREATMENT
ATE408601T1 (en) FREDERICAMYCIN DERIVATIVES
EA200700851A1 (en) OBTAINING AND APPLICATION OF BIPHENYL-4-ILKARBONYLAMINO ACID DERIVATIVES FOR TREATMENT OF OBESITY
BR0312729A (en) New indole-3-sulfur derivatives
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
NO20065847L (en) Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase
ATE416177T1 (en) HETARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS
BRPI0413490A (en) new compounds
CY1119841T1 (en) COMPOSITION OF INVIVORAL INHIBITOR FOR IN VIVO THERAPEUTIC USE
ATE469674T1 (en) 5-AMINOLEVULIC ACID DERIVATIVES FOR THE TREATMENT OF ACNE
BRPI0418031A (en) phosphonate-substituted kinase inhibitors
DE50311898D1 (en) FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT
HRP20050041B1 (en) USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN
EA200802223A1 (en) 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS
ATE554084T1 (en) N-HYDROXYACRYLAMIDE COMPOUNDS
BR0115936A (en) Substituted 2-anilino benzimidazoles and their application as inhibitors of nhe
BRPI0416287A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by accß inhibitors and their use
BRPI0517435A (en) triazoles useful as protein kinase inhibitors
ATE323490T1 (en) FARNESYL PROTEIN TRANSFERA INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
DE50109156D1 (en) MEDICINE TO TREAT DISORDERS OF THE TRACHEO BRONCHIAL TRAIN, IN PARTICULAR THE COPD
CY1109569T1 (en) Substituted cyclohexane-1,4-diamine derivatives
BRPI0514549A (en) pyrrol-naphthyl acids as inhibitors of pai-1
DE602004014823D1 (en) SELECTIVE NOREPINEPHRINE RECOVERY INHIBITOR FOR THE TREATMENT OF HITZEWALLUNGEN

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.